A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

Adenoviral Infection Clinical Trial

Official title: A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)

Status Terminated

Clinical Trial Summary

PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral) is an investigational vaccine in development for the indication of active immunization against adenovirus infection. The primary goals of this Phase 1 study are to evaluate safety, pharmacodynamics (viral shedding), and immunogenicity of PXVX0047.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenoviral Infection
• Adenoviridae Infections

• NCT number: NCT03160339
• Study type: Interventional
• Source: Emergent BioSolutions
• Status: Terminated
• Phase: Phase 1
• Start date: May 1, 2017
• Completion date: November 27, 2017